アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Fusion protein corresponding to Human Cannabinoid Receptor I aa 1-99 (N terminal).
Our Abpromise guarantee covers the use of ab3558 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC||1/1000. Immunocytochemical staining of CB1 in AtT20 cells transfected with the rat CB1 gene yields a pattern consistent with plasma membrane staining.|
|WB||1/250. By Western blot, this antibody detects an ~60 kDa protein representing CB1 from rat brain homogenate.|
|IP||Use at an assay dependent concentration. PubMed: 22387618|
|IHC-P||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration. PubMed: 20206138|
Quantification of CB1 and CB2 receptor surface expression in primary Human and HaCaT keratinocytes. (A) FL-1 shows autofluorescence (black population), non-specific binding of secondary antibody (dark grey population) and specific immunofluorescence obtained with CB1 (ab3558) and CB2 (ab3561) receptor antibodies, respectively (light grey population). Histogram shows representative measurement (5000 cells counted). (B) Differences in CB receptor expression between primary and HaCaT keratinocytes, showing marked increased expression of CB2 in primary keratinocytes (geo mean corrected for non-specific binding of secondary Ab). Data show mean values ±SEM obtained with two human primary keratinocyte samples and HaCaT cells, each measured three times.
ab3558 at a 1:1000 dilution staining Rat CB1 in transfected AtT20 cells by immunocytochemistry.